Compare RDZN & NORD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RDZN | NORD |
|---|---|---|
| Founded | 2015 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Professional Services |
| Sector | Finance | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.7M | 95.5M |
| IPO Year | 2021 | 2005 |
| Metric | RDZN | NORD |
|---|---|---|
| Price | $0.98 | $2.85 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | ★ 260.2K | 15.7K |
| Earning Date | 11-24-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.12 | 31.25 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $55,021,792.00 | $3,346.00 |
| Revenue This Year | $41.04 | N/A |
| Revenue Next Year | $78.38 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 24.21 | N/A |
| 52 Week Low | $0.98 | $2.70 |
| 52 Week High | $2.56 | $5.28 |
| Indicator | RDZN | NORD |
|---|---|---|
| Relative Strength Index (RSI) | 36.83 | 18.64 |
| Support Level | N/A | N/A |
| Resistance Level | $1.44 | $3.52 |
| Average True Range (ATR) | 0.09 | 0.57 |
| MACD | -0.01 | -0.19 |
| Stochastic Oscillator | 11.64 | 12.05 |
Roadzen Inc is an insurance technology company on a mission to transform auto insurance powered by AI. Its clients comprise insurers, fleets, and carmakers to small fleets, brokers, and insurance agents that use Roadzen's technology to build new products, sell insurance, process claims, and improve road safety. The company's work in telematics and computer vision has earned recognition as an AI innovator by publications such as Forbes, Fortune, and Financial Express. Geographically, the company operates in India, United States of America, United Kingdom, and China. It generates maximum revenue form India.
Nordicus Partners Corp specializes in developing breakthrough therapeutics for diseases with unmet medical needs. The Company focuses on acquiring and developing drugs from biotech companies in the Nordics, a region known for its scientists, life sciences ecosystem, and drug discoveries and developments. Its current portfolio includes the preclinical biotechnology companies Orocidin A/S, Bio-Convert A/S, and NoviThera ApS. The Company is dedicated to developing breakthrough therapeutics in diseases with unmet medical needs, starting with oral disorders. It operates in the segment focused on developing medicines supporting oral health.